0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Viewpoint |

Unintended Consequences of Regulatory Initiatives in Childhood Cancer Drug Development

Peter C. Adamson, MD1
[+] Author Affiliations
1Division of Clinical Pharmacology and Therapeutics, The Children’s Hospital of Philadelphia, Pennsylvania
JAMA Pediatr. 2013;167(10):886-887. doi:10.1001/jamapediatrics.2013.2488.
Text Size: A A A
Published online

Extract

Prior to 1997, and almost 30 years after Shirkey’s editorial1 that coined the phrase “therapeutic orphan,” the legislative and regulatory efforts to address the issue of labeling medications for the safe and effective use by children were, by and large, unsuccessful. With an estimated 75% of the drugs marketed in the United States lacking essential pediatric data,2 it would take a new legislative effort, first proposed in 1994 by Senator Nancy Kassebaum of Kansas, that incorporated both an incentive and a requirement for industry to conduct appropriate pediatric studies. In 1997, the Food and Drug Administration Modernization Act (FDAMA), which provided an additional 6 months of marketing exclusivity to industry as incentive, was signed into law, catalyzing the development and conduct of a range of pediatric clinical investigations.3 The FDAMA, the incentive, coupled with the Pediatric Final Rule, the requirement, were subsequently replaced by the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), now in place for a decade. The Institute of Medicine’s 2012 report on the studies conducted under BPCA and PREA found that important information to guide clinical care for children was emerging from these studies, and noted a trend in improvement in the quality of studies and reporting of results over time.4

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 3

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
Jobs
JAMAevidence.com

Care at the Close of Life EDUCATION GUIDES
Caring for the Child With Cancer at the Close of Life

brightcove.createExperiences();